{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:49:12Z","timestamp":1792698552468,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005036","name":"University of Bergen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106702","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T06:36:43Z","timestamp":1755931003000},"page":"106702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effect of early highly effective treatment compared to an escalating treatment strategy in multiple sclerosis"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7782-6324","authenticated-orcid":false,"given":"Hilde","family":"Norborg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Harald","family":"Aarseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Mannseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5vard Nyhagen","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Grytten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Wergeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.msard.2025.106702_bib0015","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat. Med."},{"issue":"8","key":"10.1016\/j.msard.2025.106702_bib0022","doi-asserted-by":"crossref","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2025.106702_bib0017","doi-asserted-by":"crossref","first-page":"e1460","DOI":"10.1002\/wics.1460","article-title":"The Akaike information criterion: background, derivation, properties, application, interpretation, and refinements","volume":"11","author":"Cavanaugh","year":"2019","journal-title":"WIREs Comput. Stat."},{"issue":"5","key":"10.1016\/j.msard.2025.106702_bib0026","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16583","article-title":"Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM study","volume":"32","author":"Cohen","year":"2025","journal-title":"Eur. J. Neurol."},{"issue":"15","key":"10.1016\/j.msard.2025.106702_bib0020","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s40265-023-01942-0","article-title":"Escalation versus induction\/high-efficacy treatment strategies for relapsing multiple sclerosis: which is best for patients?","volume":"83","author":"Edan","year":"2023","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.msard.2025.106702_bib0007","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00228-018-2429-1","article-title":"Wettermark B, von Euler M. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations","volume":"74","author":"Eriksson","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.msard.2025.106702_bib0001","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","article-title":"Early use of high-efficacy disease\u2011modifying therapies makes the difference in people with multiple sclerosis: an expert opinion","volume":"269","author":"Filippi","year":"2022","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2025.106702_bib0018","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing-remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2025.106702_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104803","article-title":"Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries","volume":"76","author":"Hrnciarova","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106702_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211019574","article-title":"Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106702_bib0014","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1749-6632.1984.tb14805.x","article-title":"Disability rating scales in multiple sclerosis","volume":"436","author":"Kurtzke","year":"1984","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"11","key":"10.1016\/j.msard.2025.106702_bib0013","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2025.106702_bib0023","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106702_bib0010","first-page":"292","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology","volume":"69","author":"Polman","year":"2011","journal-title":"Feb"},{"issue":"6","key":"10.1016\/j.msard.2025.106702_bib0012","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106702_bib0009","article-title":"Approach to managing the initial presentation of multiple sclerosis: a worldwide practice survey","volume":"15","author":"Roberts","year":"2025","journal-title":"Neurol. Clin. Pr."},{"key":"10.1016\/j.msard.2025.106702_bib0016","volume":"81","author":"Rubin","year":"2004"},{"issue":"3","key":"10.1016\/j.msard.2025.106702_bib0004","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ane.12712","article-title":"Safety concerns and risk management of multiple sclerosis therapies","volume":"136","author":"Soelberg Sorensen","year":"2017","journal-title":"Acta Neurol. Scand."},{"issue":"10","key":"10.1016\/j.msard.2025.106702_bib0021","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106702_bib0006","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial","volume":"21","author":"Svenningsson","year":"2022","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106702_bib0011","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106702_bib0005","article-title":"Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis - a cohort study","volume":"7","author":"Torgauten","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"Suppl 1","key":"10.1016\/j.msard.2025.106702_bib0002","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ene.12883","article-title":"Disease-modifying treatments for multiple sclerosis - a review of approved medications","volume":"23","author":"Torkildsen","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106702_bib0024","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00415-021-10850-w","article-title":"Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review","volume":"269","author":"Washington","year":"2022","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106702_bib0003","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/138161212799040501","article-title":"Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects","volume":"18","author":"Weber","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.msard.2025.106702_bib0008","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","article-title":"Optimizing treatment success in multiple sclerosis","volume":"263","author":"Ziemssen","year":"2016","journal-title":"J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:19:10Z","timestamp":1774999150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":26,"alternative-id":["S2211034825004444"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106702","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of early highly effective treatment compared to an escalating treatment strategy in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106702"}}